Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
NextCure Inc
NASDAQ NXTC
Data sourced from
and
and
NextCure Inc Net Operating Profit After Tax (NOPAT) 2 year CAGR for the quarter ending December 31, 2023
NextCure Inc Net Operating Profit After Tax (NOPAT) 2 year CAGR is NA for the quarter ending December 31, 2023. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
NextCure Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2023 was -15,135,091.39, a 18.28% change year over year.
-
NextCure Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2022 was -18,520,815.55.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: NXTC
| CEO | Mr. Michael S. Richman MSBA |
| IPO Date | May 9, 2019 |
| Location | United States |
| Headquarters | 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 |
| Employees | 82 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email